Innventure (INV) Q4 2024 earnings summary

Executive summary

• Achieved key milestones in 2024, including commercial product launches for AeroFlexx and Accelsius, and the launch of Refinity (also referred to as Raffiney) in collaboration with Dow Chemical.

• Completed a business combination and began trading on NASDAQ in October 2024, marking the transition to a public company.

• Expanded multinational partnerships, now collaborating with Procter & Gamble, Nokia, Dow, and others.

• Signed new partnerships and expanded product lines across operating companies, with strong momentum expected into 2025.

Financial highlights

• Total revenue for 2024 was $1.22 million, primarily from AeroFlexx and Accelsius' first commercial sales.

• Adjusted EBITDA loss for 2024 was $27.9 million, driven by cost of sales, R&D, marketing, and non-recurring expenses related to the business combination.

• Net loss for 2024 was $98.8 million, with significant adjustments for transaction costs, fair value changes, and stock-based compensation.

• Cash, cash equivalents, and restricted cash at year-end 2024 totaled $11.1 million, up from $2.6 million at year-end 2023.

• Total assets increased to $905.3 million at December 31, 2024.

Outlook and guidance

• 2025 is expected to be a revenue growth inflection year, with most growth in the second half, particularly from Accelsius and AeroFlexx as new contracts and certifications unlock further orders.

• Management expects continued momentum and further developments in 2025, including expansion of multinational partnerships and operating company launches.

• Focused on pacing capital investments with revenue visibility and maintaining disciplined cost management.